Psychedelic Drugs Market - 2026-2033
Psychedelic Drugs Market reached US$3.71 billion in 2025 and is expected to reach US$9.20 billion by 2033, growing with a CAGR of 12.10% during the forecast period 2026-2033.
The Psychedelic Drugs Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Psychedelic Drugs Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Drug Type
Both primary and secondary data sources have been used in the global Psychedelic Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Psychedelic Drugs Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Psychedelic Drugs Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Drug Type
- Lysergic Acid Diethylamide*
- Gamma-Hydroxybutyric Acid
- Ketamine
- Psilocybin
- Others
- Treatment-Resistant Depression*
- Opiate Addiction
- Post-Traumatic Stress Disorder
- Narcolepsy
- Panic Disorders
- Others
- Hospital Pharmacies*
- Retail Pharmacies
- Online Pharmacies
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Psychedelic Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY DRUG TYPE
4.1. Snippet by Application
4.2. Snippet by Distribution Channel
4.3. Snippet by Region
5. DYNAMICS
5.1. Impacting Factors
5.1.1. Drivers
5.1.1.1. Rising Prevalence of Mental Health Disorders
5.1.1.2. Advancements in Psychedelic Research and Clinical Trials
5.1.1.3. XX
5.2. Restraints
5.2.1. Regulatory and Legal Challenges
5.2.1.1. Lack of Standardized Dosage and Long-Term Safety Data
5.2.1.2. XX
5.2.2. Opportunity
5.2.2.1. Expansion into Emerging Markets with Evolving Drug Policies
5.2.2.2. XX
5.2.3. Impact Analysis
6. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
6.1. Market Leaders and Pioneers
6.1.1. Emerging Pioneers and Prominent Players
6.1.2. Established leaders with largest largest-selling Brand
6.1.3. Market leaders with established products & Services
6.2. CXO Perspectives
6.3. Latest Developments and Breakthroughs
6.4. Regulatory and Reimbursement Landscape
6.4.1. North America
6.4.2. Europe
6.4.3. Asia Pacific
6.4.4. South America
6.4.5. Middle East & Africa
6.5. Porter’s Five Force Analysis
6.6. Supply Chain Analysis
6.7. Patent Analysis
6.8. SWOT Analysis
6.9. Unmet Needs and Gaps
6.10. Recommended Strategies for Market Entry and Expansion
6.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
6.12. Pricing Analysis and Price Dynamics
6.13. Key Opinion Leaders
7. GLOBAL PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Lysergic Acid Diethylamide*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Gamma-Hydroxybutyric Acid
7.4. Ketamine
7.5. Psilocybin
7.6. Others
8. GLOBAL PSYCHEDELIC DRUGS MARKET, BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Treatment-Resistant Depression*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Opiate Addiction
8.4. Post-Traumatic Stress Disorder
8.5. Narcolepsy
8.6. Panic Disorders
8.7. Others
9. GLOBAL PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)?
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. PSYCHEDELIC DRUGS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
11. INTRODUCTION
11.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.1. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.6.1. U.S.
11.2.6.2. Canada
11.2.6.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.6.1. Germany
11.3.6.2. U.K.
11.3.6.3. France
11.3.6.4. Spain
11.3.6.5. Italy
11.3.6.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.6.1. Brazil
11.4.6.2. Argentina
11.4.6.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.6.1. China
11.5.6.2. India
11.5.6.3. Japan
11.5.6.4. South Korea
11.5.6.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
13. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
13.1. Market Share Analysis and Positioning Matrix
13.2. Strategic Partnerships, Mergers & Acquisitions
13.3. Key Developments in Product Type Portfolios and Innovations
13.4. Company Benchmarking
14. COMPANY PROFILES
14.1. Compass Pathways*
14.1.1. Company Overview
14.1.2. Product Portfolio
14.1.3. Financial Overview
14.1.3.1. Company Revenue
14.1.3.2. Geographical Revenue Shares
14.1.3.3. Revenue Forecasts
14.1.4. Key Developments
14.1.4.1. Mergers & Acquisitions
14.1.4.2. Key Product Type Development Activities
14.1.4.3. Regulatory Approvals, etc.
14.1.5. SWOT Analysis
14.2. MindMed
14.3. Hikma Pharmaceuticals
14.4. Celon Pharmaceuticals
14.5. Cybin Corp
14.6. Pfizer Inc.
14.7. Jazz Pharmaceuticals Inc.
14.8. Atai Life Sciences N.V.
14.9. PharmaTher Holdings Ltd.
14.10. GH Research PLC (*LIST NOT EXHAUSTIVE)
15. ASSUMPTIONS AND RESEARCH METHODOLOGY
15.1. Data Collection Methods
15.2. Data Triangulation
15.3. Forecasting Techniques
15.4. Data Verification and Validation
16. APPENDIX
16.1. About Us and Services
16.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS
3.1. Key Trends and Future Projections
4. SNIPPET BY DRUG TYPE
4.1. Snippet by Application
4.2. Snippet by Distribution Channel
4.3. Snippet by Region
5. DYNAMICS
5.1. Impacting Factors
5.1.1. Drivers
5.1.1.1. Rising Prevalence of Mental Health Disorders
5.1.1.2. Advancements in Psychedelic Research and Clinical Trials
5.1.1.3. XX
5.2. Restraints
5.2.1. Regulatory and Legal Challenges
5.2.1.1. Lack of Standardized Dosage and Long-Term Safety Data
5.2.1.2. XX
5.2.2. Opportunity
5.2.2.1. Expansion into Emerging Markets with Evolving Drug Policies
5.2.2.2. XX
5.2.3. Impact Analysis
6. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
6.1. Market Leaders and Pioneers
6.1.1. Emerging Pioneers and Prominent Players
6.1.2. Established leaders with largest largest-selling Brand
6.1.3. Market leaders with established products & Services
6.2. CXO Perspectives
6.3. Latest Developments and Breakthroughs
6.4. Regulatory and Reimbursement Landscape
6.4.1. North America
6.4.2. Europe
6.4.3. Asia Pacific
6.4.4. South America
6.4.5. Middle East & Africa
6.5. Porter’s Five Force Analysis
6.6. Supply Chain Analysis
6.7. Patent Analysis
6.8. SWOT Analysis
6.9. Unmet Needs and Gaps
6.10. Recommended Strategies for Market Entry and Expansion
6.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
6.12. Pricing Analysis and Price Dynamics
6.13. Key Opinion Leaders
7. GLOBAL PSYCHEDELIC DRUGS MARKET, BY DRUG TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Lysergic Acid Diethylamide*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Gamma-Hydroxybutyric Acid
7.4. Ketamine
7.5. Psilocybin
7.6. Others
8. GLOBAL PSYCHEDELIC DRUGS MARKET, BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Treatment-Resistant Depression*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Opiate Addiction
8.4. Post-Traumatic Stress Disorder
8.5. Narcolepsy
8.6. Panic Disorders
8.7. Others
9. GLOBAL PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)?
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. PSYCHEDELIC DRUGS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
11. INTRODUCTION
11.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.1. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.6.1. U.S.
11.2.6.2. Canada
11.2.6.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.6.1. Germany
11.3.6.2. U.K.
11.3.6.3. France
11.3.6.4. Spain
11.3.6.5. Italy
11.3.6.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.6.1. Brazil
11.4.6.2. Argentina
11.4.6.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.6.1. China
11.5.6.2. India
11.5.6.3. Japan
11.5.6.4. South Korea
11.5.6.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
13. COMPETITIVE OVERVIEW AND KEY MARKET PLAYERS
13.1. Market Share Analysis and Positioning Matrix
13.2. Strategic Partnerships, Mergers & Acquisitions
13.3. Key Developments in Product Type Portfolios and Innovations
13.4. Company Benchmarking
14. COMPANY PROFILES
14.1. Compass Pathways*
14.1.1. Company Overview
14.1.2. Product Portfolio
14.1.3. Financial Overview
14.1.3.1. Company Revenue
14.1.3.2. Geographical Revenue Shares
14.1.3.3. Revenue Forecasts
14.1.4. Key Developments
14.1.4.1. Mergers & Acquisitions
14.1.4.2. Key Product Type Development Activities
14.1.4.3. Regulatory Approvals, etc.
14.1.5. SWOT Analysis
14.2. MindMed
14.3. Hikma Pharmaceuticals
14.4. Celon Pharmaceuticals
14.5. Cybin Corp
14.6. Pfizer Inc.
14.7. Jazz Pharmaceuticals Inc.
14.8. Atai Life Sciences N.V.
14.9. PharmaTher Holdings Ltd.
14.10. GH Research PLC (*LIST NOT EXHAUSTIVE)
15. ASSUMPTIONS AND RESEARCH METHODOLOGY
15.1. Data Collection Methods
15.2. Data Triangulation
15.3. Forecasting Techniques
15.4. Data Verification and Validation
16. APPENDIX
16.1. About Us and Services
16.2. Contact Us
More Publications
Clinically Isolated Syndrome Treatment Market - 2024-2031
US$ 3,400.00
December 2023
64 pages
Anti Depression Drugs Market - 2024-2031
US$ 3,400.00
February 2025
47 pages
Huntington's Disease Market - 2025-2033
US$ 3,400.00
June 2025
46 pages
Edaravone Market - 2024-2031
US$ 3,400.00
November 2024
35 pages
Benzodiazepine Drugs Market - 2024-2031
US$ 3,400.00
February 2026
46 pages
